{"id":578879,"date":"2021-12-13T18:22:01","date_gmt":"2021-12-13T18:22:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=578879"},"modified":"2021-12-13T18:22:01","modified_gmt":"2021-12-13T18:22:01","slug":"osteoporosis-market-to-register-incremental-growth-during-the-forecast-period-2030-asserts-delveinsight-key-companies-amgen-pfizer-roche-novartis-pfenex-haoma-medica-eli-lilly-and-others","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/osteoporosis-market-to-register-incremental-growth-during-the-forecast-period-2030-asserts-delveinsight-key-companies-amgen-pfizer-roche-novartis-pfenex-haoma-medica-eli-lilly-and-others_578879.html","title":{"rendered":"Osteoporosis Market to Register Incremental Growth During the Forecast Period 2030, Asserts DelveInsight | Key Companies &#8211; Amgen, Pfizer, Roche, Novartis, Pfenex, Haoma Medica, Eli Lilly, and Others"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/uploads\/1585677425.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Osteoporosis Market to Register Incremental Growth During the Forecast Period 2030, Asserts DelveInsight | Key Companies - Amgen, Pfizer, Roche, Novartis, Pfenex, Haoma Medica, Eli Lilly, and Others\" src=\"https:\/\/www.abnewswire.com\/uploads\/1585677425.jpeg\" alt=\"Osteoporosis Market to Register Incremental Growth During the Forecast Period 2030, Asserts DelveInsight | Key Companies - Amgen, Pfizer, Roche, Novartis, Pfenex, Haoma Medica, Eli Lilly, and Others\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>Delveinsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">DelveInsight&#8217;s &#8220;Osteoporosis Market Insights, Epidemiology, and Market Forecast 2030&#8221; report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Osteoporosis Market Size and Share in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/div>\n<p style=\"text-align: justify;\" dir=\"ltr\">The <strong>Osteoporosis market report<\/strong> covers emerging drugs, current treatment practices, market share of the individual therapies, current and forecasted market size from 2017 to 2030. It evaluates the current treatment practice\/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><img decoding=\"async\" style=\"display: block; margin-left: auto; margin-right: auto;\" title=\"Osteoporosis Market \" src=\"https:\/\/www.abnewswire.com\/uploads\/b707e2620c1c09f0642d562701385c91.jpg\" alt=\"Osteoporosis Market \" \/><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Osteoporosis: An Overview<\/strong><\/p>\n<p style=\"text-align: justify;\"><em>Osteoporosis is defined as a systemic skeletal disease characterized by low bone mass and microarchitectural deterioration of bone tissue, with a consequent increase in bone fragility and susceptibility to fracture. This well-established definition, developed by the international consensus in 1993, captures two important characteristics of the disease: its adverse effects on bone mass and microstructure, and the clinical outcome of fracture.<\/em><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Osteoporosis Market Key Facts<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\"><em>The United States accounts for the largest market size of Osteoporosis, in comparison to EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.<\/em><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><em>The total diagnosed prevalent population of osteoporosis in the seven major markets was found to be 28,097,783 cases in 2017. The total diagnosed prevalent population of Osteoporosis in the United States was found to be 6,380,754 cases in 2017, which is expected to increase by 2030.<\/em><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><em>In the EU5 countries, the total diagnosed prevalent population of Osteoporosis was found to be maximum in Germany with 4,309,667 cases, followed by Italy with 3,840,703 cases in 2017. France had the lowest number of diagnosed prevalent cases of osteoporosis with 2,786,944 cases in 2017.<\/em><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><em>Japan accounted for 4,513,275 cases of diagnosed prevalent osteoporosis in 2017, which is expected to increase in the forecast period 2020&ndash;2030.<\/em><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><em>Around the world, 1 in 3 women and 1 in 5 men aged fifty years and over are at risk of an osteoporotic fracture. In fact, an osteoporotic fracture is estimated to occur every 3 seconds.<\/em><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><em>As per Delveinsight, up to 30% of patients suffering from a hip fracture will require long-term nursing-home care.<\/em><\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Osteoporosis Market<\/strong><\/p>\n<p style=\"text-align: justify;\"><em><strong>The market size of Osteoporosis in the seven major markets was 9,442.73 USD Million in 2017, which will increase by 2030.&nbsp;Osteoporosis market size is expected to increase during the forecast owing to the rise in the number of prevalent cases in the 7MM.<\/strong><\/em><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted Osteoporosis market size and share by analyzing the impact of current therapies on the market, unmet needs, drivers, and barriers, and demand for better technology.&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The report gives a thorough detail of the <strong>Osteoporosis market trend<\/strong> for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Get FREE sample copy at:&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/osteoporosis-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\">Osteoporosis Therapeutics Market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Osteoporosis Epidemiology<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The epidemiology section covers insights about the historical and current <strong>Osteoporosis patient pool and forecasted trends<\/strong> for every seven major countries from 2017 to 2030. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.&nbsp;&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Osteoporosis Drugs Uptake and Pipeline Development Activities<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the <strong>Osteoporosis market<\/strong> or expected to get launched in the market during the study period. The analysis covers Osteoporosis market uptake by drugs; patient uptake by therapies; and sales of each drug.&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">Report&rsquo;s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The report also covers the <strong>Osteoporosis Pipeline Development Activities<\/strong> and provides valuable insights about different therapeutic candidates in Phase II, and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyses the recent Development such as collaborations, acquisitions, and mergers, licensing patent details, and other information for emerging therapies.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/osteoporosis-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\"><strong>Osteoporosis Therapeutics Analysis<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><em>The current market is already dominated by biosimilars and generics, which are quite promising and have the potential for the treatment of osteoporosis. However the pipeline for Osteoporosis does not hold significant products, it has few products, which are being developed by certain key players.<\/em><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Key companies in the Osteoporosis Market include:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Amgen<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Haoma Medica<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Pfizer<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Radius Health<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">TherapeuticsMD<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Roche<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Novartis Pharmaceuticals<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Eli Lilly<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Pfenex<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\">And many others.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Osteoporosis therapies covered in the report include:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Alendronate\/Zoledronic Acid<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">NaQuinate<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Evenity (Romosozumab-aqqg)<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Prolia (Denosumab)<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Fablyn (Lasofoxifene)<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Duavee (conjugated estrogens\/bazedoxifene)<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Tymlos (abaloparatide)<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Bijuva (estradiol and progesterone)<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Boniva (ibandronate sodium)<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Bonsity (PF708)<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\">And many more.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><em>The pipeline of osteoporosis marks a significant unmet need due to the availability of few products. There is a need for developing new drugs in the pipeline so that the emerging market of osteoporosis can prosper as well.<\/em><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Request for Sample @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/osteoporosis-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\">Osteoporosis Emerging Therapies and Key Companies<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Table of Content<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">1. Key Insights<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">2. Executive Summary&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">3. Osteoporosis Competitive Intelligence Analysis<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">4. Osteoporosis Market Overview at a Glance<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">5. Osteoporosis Disease Background and Overview<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">6. Osteoporosis Patient Journey<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">7. Osteoporosis Epidemiology and Patient Population<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">8. Osteoporosis Treatment Algorithm, Current Treatment, and Medical Practices<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">9. Osteoporosis Unmet Needs<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">10. Key Endpoints of Osteoporosis Treatment<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">11. Osteoporosis Marketed Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">12. Osteoporosis Emerging Therapies<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">13. Osteoporosis Seven Major Market Analysis<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">14. Attribute Analysis<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">15. Osteoporosis Market Outlook (7 major markets)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">16. Osteoporosis Access and Reimbursement Overview<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">17. KOL Views on the Osteoporosis Market.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">18. Osteoporosis Market Drivers<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">19. Osteoporosis Market Barriers<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">20. Appendix<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">21. DelveInsight Capabilities<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">22. Disclaimer<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>*The table of contents is not exhaustive; the final content may vary.&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Get FREE sample copy at:&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/osteoporosis-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\">https:\/\/www.delveinsight.com\/sample-request\/osteoporosis-market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Latest Report By DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/down-syndrome-market\">Down Syndrome Market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">DelveInsight&#8217;s &#8220;Down Syndrome Market Insights, Epidemiology, and Market Forecast 2030&#8221; report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Down Syndrome market size and shares analysis in the 7MM (i.e the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>About DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56421.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Shruti Thakur<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=osteoporosis-market-to-register-incremental-growth-during-the-forecast-period-2030-asserts-delveinsight-key-companies-amgen-pfizer-roche-novartis-pfenex-haoma-medica-eli-lilly-and-others\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 09650213330<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> NV<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=osteoporosis-market-to-register-incremental-growth-during-the-forecast-period-2030-asserts-delveinsight-key-companies-amgen-pfizer-roche-novartis-pfenex-haoma-medica-eli-lilly-and-others\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Delveinsight Business Research LLP DelveInsight&#8217;s &#8220;Osteoporosis Market Insights, Epidemiology, and Market Forecast 2030&#8221; report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Osteoporosis Market Size and Share in the United States, EU5 (Germany, Spain, &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/osteoporosis-market-to-register-incremental-growth-during-the-forecast-period-2030-asserts-delveinsight-key-companies-amgen-pfizer-roche-novartis-pfenex-haoma-medica-eli-lilly-and-others_578879.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[435,405,406,403,404],"tags":[],"class_list":["post-578879","post","type-post","status-publish","format-standard","hentry","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-UK","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/578879","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=578879"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/578879\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=578879"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=578879"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=578879"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}